Etoposide
Brand Names: Vepesid, Avopef
Methodology & AI Transparency ⓘ
Etoposide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 20 mg/mL Injection and 50 mg/1 Capsule under FDA code 0143-9376, 69238-2811 (manufactured/labeled by Hikma Pharmaceuticals USA Inc.), Etoposide delivers intravenous-route topoisomerase inhibitor pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: Real-world cohort score of 74% across 5 de-identified Etoposide entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $101.25 mail/discount cash up to $248.06 uninsured retail (federal NADAC $2.2900).
- 4 Top reported side effects / signs: Most commonly reported Etoposide tolerability events: nausea (8.8%), headache (8.3%), dizziness (6.8%).
Ask our AI Specialists anything about Etoposide
Etoposide Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 20 mg/mL Injection and 50 mg/1 Capsule under FDA code 0143-9376, 69238-2811 (manufactured/labeled by Hikma Pharmaceuticals USA Inc.), Etoposide delivers intravenous-route topoisomerase inhibitor pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Etoposide reflects topoisomerase inhibitor pathway engagement after intravenous-route dosing (20 mg/mL Injection and 50 mg/1 Capsule, manufactured/labeled by Hikma Pharmaceuticals USA Inc., NDC 0143-9376, 69238-2811), supporting titratable maintenance pharmacotherapy.
Pharmacokinetic profiling of Etoposide demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 9–16 hour t½ intervals for Etoposide with Complete (~100%) parenteral systemic delivery for Etoposide (20 mg/mL Injection) systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar etoposide conjugates, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after etoposide administration.
Titration schedules for Etoposide (20 mg/mL Injection → 50 mg/1 Capsule → 20 mg/mL Injection, Solution → 20 mg/mL Injection, Solution, Concentrate → 100 mg/5mL Injection) require excluding history of severe allergic sensitivity to etoposide active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-07-01 etoposide labeling; real-world patient logs highlight nausea (8.8% of reports), headache (8.3% of reports), dizziness (6.8% of reports) alongside a 74.00% Worth-It consensus.
Verify medication reconciliation lists so Etoposide is not inadvertently duplicated with another topoisomerase inhibitor.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Etoposide dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Etoposide active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-07-01 Etoposide labeling
Logged Side-Effect Incidence (5 Reports)
Etoposide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Etoposide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in: What a 227-Participant Study Found Long-term follow-up data from RATIONALE-312 reported that. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2026-06-15 • Phase III Randomized Trial | N = 227 | 88/100 | PMID 41796863 ↗ |
| Can This Approach Help? Inside the Latest Research on Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line From the US payer perspective, the first-line treatment for ES-SCLC with pembrolizumab plus EP was not cost-effective compared with placebo plus EP. PloS one • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34780478 ↗ |
| New Insights on Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer:: What a 268-Participant Study Found These findings support the use of durvalumab plus EP as first-line standard of care for ES-SCLC. Clinical lung cancer • 2025-12-15 • Phase III Randomized Trial | N = 268 | 87/100 | PMID 40887341 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in As the CONVERT trial did not demonstrate the superiority of OD RT and this regimen had a slightly worse toxicity profile after 80 months of follow-up, 45 Gy BD should remain the standard of care in limited stage small cell... International journal of radiation oncology, biology, physics • 2024-08-01 • Phase III Randomized Trial | N = 164 | 82/100 | PMID 38521132 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid Rates of CR/CRi were not different between treatment arms; infections were more common in ATRA beyond treatment cycle one. Scientific reports • 2023-09-08 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37684299 ↗ |
Etoposide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.2900/unit (~$68.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $248.06 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $101.25 / mo | View logs ↓ |
Etoposide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Etoposide RxNorm Concept ID | RXN-01439376-2322 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.2900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $248.06 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $101.25 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Etoposide Patient Community, Cohort Filters & Dosage Logs
Cross-verified Etoposide (topoisomerase inhibitor) monograph synthesizing RxNorm RXN-01439376-2322, openFDA FAERS signals, and $101.25–$248.06 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Etoposide community threads and patient logs by age, biological sex, dosage, and treatment duration.